Waltham, MA / November 25, 2025 — LarmorBio is excited to share that Michael J. McPhaul, MD, will present clinical data from our collaboration with Quest Diagnostics at the 24th World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (Dec 3–5, Los Angeles).
The talk will highlight a novel blood test that captures the earliest transitions in metabolic health—opening a new window into early disease detection and personalized intervention.
About LarmorBio, Inc.
LarmorBio, Inc. is a life sciences and clinical diagnostics company developing the BioScan-NMR™ platform, a next-generation microscale nuclear magnetic resonance (“NMR”) system for rapid, label-free phenotyping of live cells and micro-sized biological samples. Founded as a Massachusetts Institute of Technology (MIT) spin-off, LarmorBio’s technology is designed to deliver molecular-level diagnostic information from small sample volumes in minutes, without the cryogenics, dedicated infrastructure, or specialized personnel required by conventional NMR instrumentation. The Company’s platform supports applications across bioprocessing, cell and gene therapy development, and clinical diagnostics.
